Prognosis and prognostic factors of patients with mesothelioma: a population-based study

S. van der Bij; H. Koffijberg; J. A. Burgers; P. Baas; M. J. van de Vijver; B. A. J. M. de Mol; K. G. M. Moons

doi:https://doi.org/10.1038/bjc.2012.245

Prognosis and prognostic factors of patients with mesothelioma: a population-based study

S. van der Bij, H. Koffijberg, J. A. Burgers, P. Baas, M. J. van de Vijver, B. A. J. M. de Mol, K. G. M. Moons

Research output: Contribution to journal › Article › Academic › peer-review

45 Citations (Scopus)

Abstract

BACKGROUND: It is important to regularly update survival estimates of patients with malignant mesothelioma as prognosis may vary according to epidemiologic factors and diagnostic and therapeutic management. METHODS: We assessed overall (baseline) survival as well as related prognostic variables in a large cohort of 1353 patients with a confirmed diagnosis of malignant mesothelioma between 2005 and 2008. RESULTS: About 50% of the patients were 70 years or older at diagnosis and the median latency time since start of asbestos exposure was 49 years. One year after diagnosis, 47% of the patients were alive, 20% after 2 years and 15% after 3 years. Prognostic variables independently associated with worse survival were: older age (HR = 1.04 per year 95% CI (1.03-1.06)), sarcomatoid subtype (HR = 2.45 95% CI (2.06-2.90)) and non-pleural localisation (HR = 1.67 95% CI (1.26-2.22)). CONCLUSION: Survival of patients with malignant mesothelioma is still limited and depends highly on patient age, mesothelioma subtype and localisation. In addition, a substantial part of the patients had a long latency time between asbestos exposure and diagnosis. British Journal of Cancer (2012) 107, 161-164. doi: 10.1038/bjc.2012.245 www.bjcancer.com Published online 29 May 2012 (C) 2012 Cancer Research UK

Original language	English
Pages (from-to)	161-164
Journal	British journal of cancer
Volume	107
Issue number	1
DOIs	https://doi.org/10.1038/bjc.2012.245
Publication status	Published - 2012

Access to Document

https://doi.org/10.1038/bjc.2012.245

Cite this

@article{994de0a2c6844269a18d46507fd797c2,

title = "Prognosis and prognostic factors of patients with mesothelioma: a population-based study",

abstract = "BACKGROUND: It is important to regularly update survival estimates of patients with malignant mesothelioma as prognosis may vary according to epidemiologic factors and diagnostic and therapeutic management. METHODS: We assessed overall (baseline) survival as well as related prognostic variables in a large cohort of 1353 patients with a confirmed diagnosis of malignant mesothelioma between 2005 and 2008. RESULTS: About 50% of the patients were 70 years or older at diagnosis and the median latency time since start of asbestos exposure was 49 years. One year after diagnosis, 47% of the patients were alive, 20% after 2 years and 15% after 3 years. Prognostic variables independently associated with worse survival were: older age (HR = 1.04 per year 95% CI (1.03-1.06)), sarcomatoid subtype (HR = 2.45 95% CI (2.06-2.90)) and non-pleural localisation (HR = 1.67 95% CI (1.26-2.22)). CONCLUSION: Survival of patients with malignant mesothelioma is still limited and depends highly on patient age, mesothelioma subtype and localisation. In addition, a substantial part of the patients had a long latency time between asbestos exposure and diagnosis. British Journal of Cancer (2012) 107, 161-164. doi: 10.1038/bjc.2012.245 www.bjcancer.com Published online 29 May 2012 (C) 2012 Cancer Research UK",

author = "{van der Bij}, S. and H. Koffijberg and Burgers, {J. A.} and P. Baas and {van de Vijver}, {M. J.} and {de Mol}, {B. A. J. M.} and Moons, {K. G. M.}",

year = "2012",

doi = "https://doi.org/10.1038/bjc.2012.245",

language = "English",

volume = "107",

pages = "161--164",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Prognosis and prognostic factors of patients with mesothelioma: a population-based study

AU - van der Bij, S.

AU - Koffijberg, H.

AU - Burgers, J. A.

AU - Baas, P.

AU - van de Vijver, M. J.

AU - de Mol, B. A. J. M.

AU - Moons, K. G. M.

PY - 2012

Y1 - 2012

N2 - BACKGROUND: It is important to regularly update survival estimates of patients with malignant mesothelioma as prognosis may vary according to epidemiologic factors and diagnostic and therapeutic management. METHODS: We assessed overall (baseline) survival as well as related prognostic variables in a large cohort of 1353 patients with a confirmed diagnosis of malignant mesothelioma between 2005 and 2008. RESULTS: About 50% of the patients were 70 years or older at diagnosis and the median latency time since start of asbestos exposure was 49 years. One year after diagnosis, 47% of the patients were alive, 20% after 2 years and 15% after 3 years. Prognostic variables independently associated with worse survival were: older age (HR = 1.04 per year 95% CI (1.03-1.06)), sarcomatoid subtype (HR = 2.45 95% CI (2.06-2.90)) and non-pleural localisation (HR = 1.67 95% CI (1.26-2.22)). CONCLUSION: Survival of patients with malignant mesothelioma is still limited and depends highly on patient age, mesothelioma subtype and localisation. In addition, a substantial part of the patients had a long latency time between asbestos exposure and diagnosis. British Journal of Cancer (2012) 107, 161-164. doi: 10.1038/bjc.2012.245 www.bjcancer.com Published online 29 May 2012 (C) 2012 Cancer Research UK

AB - BACKGROUND: It is important to regularly update survival estimates of patients with malignant mesothelioma as prognosis may vary according to epidemiologic factors and diagnostic and therapeutic management. METHODS: We assessed overall (baseline) survival as well as related prognostic variables in a large cohort of 1353 patients with a confirmed diagnosis of malignant mesothelioma between 2005 and 2008. RESULTS: About 50% of the patients were 70 years or older at diagnosis and the median latency time since start of asbestos exposure was 49 years. One year after diagnosis, 47% of the patients were alive, 20% after 2 years and 15% after 3 years. Prognostic variables independently associated with worse survival were: older age (HR = 1.04 per year 95% CI (1.03-1.06)), sarcomatoid subtype (HR = 2.45 95% CI (2.06-2.90)) and non-pleural localisation (HR = 1.67 95% CI (1.26-2.22)). CONCLUSION: Survival of patients with malignant mesothelioma is still limited and depends highly on patient age, mesothelioma subtype and localisation. In addition, a substantial part of the patients had a long latency time between asbestos exposure and diagnosis. British Journal of Cancer (2012) 107, 161-164. doi: 10.1038/bjc.2012.245 www.bjcancer.com Published online 29 May 2012 (C) 2012 Cancer Research UK

U2 - https://doi.org/10.1038/bjc.2012.245

DO - https://doi.org/10.1038/bjc.2012.245

M3 - Article

C2 - 22644294

SN - 0007-0920

VL - 107

SP - 161

EP - 164

JO - British journal of cancer

JF - British journal of cancer

IS - 1

ER -